← Leaderboards
Jeffrey Paul Staab
University Of California Los Angeles
$1,599,438
Attributed
$3,198,876
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $658.5K · FY2014–18$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,198,876 · 1
By mechanism
U01$3,198,876 · 1
Top collaborators
- Robert William Baloh5 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Robert William Baloh$5,482,156
- Giovanni Coppola$6,186,082
- Joanna C Jen$4,943,809
- Sanjaya Saxena$2,670,124
- Yvette France Tache$17,660,715
Others in their field
Top investigators on “Future”
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$274,284,003
- Chanza Baytop · Westat, Inc.$271,217,917
- Everette D Joseph · Howard University$246,289,043
Research focus
FutureGait AbnormalityBaseFunctional DisabilityAdverse EffectsClinicClinical CareClinical ManagementBurden Of IllnessAffectCase StudyControl TrialDesignDiagnosisDizzinessDoseDouble-Blind MethodElementsEnrollmentEpidemiologic DataEvidence Based GuidelinesEvidence Based TreatmentControlled StudyGeneral Population
Grant awards (5)
A Phase II Trial on Rizatriptan for Vestibular Migraine$637,163
U01 · FY2018 · DC
A Phase II Trial on Rizatriptan for Vestibular Migraine$636,532
U01 · FY2017 · DC
A Phase II Trial on Rizatriptan for Vestibular Migraine$636,532
U01 · FY2016 · DC
A Phase II Trial on Rizatriptan for Vestibular Migraine$630,165
U01 · FY2015 · DC
A Phase II Trial on Rizatriptan for Vestibular Migraine$658,484
U01 · FY2014 · DC